NSAID-INDUCED PATHOLOGY OF THE GASTROINTESTINAL TRACT: WHAT IS REMAINING IN THE SHADOW?


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Since nonsteroidal anti-inflammatory drugs (NSAIDs) are effective preparations for the pathogenetic therapy of acute or chronic pain resulting from tissue damage and inflammation, the area for intended use of this class of drugs is quite wide. Therefore, practitioners have to face a frequent and serious problem such as NSAID-induced gastropathy, the clinical and pathogenetic features of which are well-understood and known. NSAIDs, however, are not only able to have a damaging effect in the gastroduodenal zone, but also cause damage to the mucous membrane of the esophagus, as well as the intestines. The infrequent compatibility of the clinical and endoscopic picture of NSAID-induced esophagitis, especially in elderly patients, the nonspecific symptomatology, as well as the difficulty of diagnosing small bowel lesions against the background of use of NSAIDs and acetylsalicylic acid (including its enteric-soluble forms), do not always allow the clinician to suspect this pathology. The lack of developed algorithms for the management of such patients also creates certain difficulties in correcting NSAID-induced lesions of the esophagus and intestines.

Толық мәтін

Рұқсат жабық

Авторлар туралы

I. Pakhomova

FSBEI HE NWSMU n.a. I.I. Mechnikov of RMH

Email: pakhomova-inna@yandex.ru
PhD, Associate Professor, Department of Propaedeutics of Internal Diseases, Gastroenterology and Dietology

I. Gubonina

MMA n.a. S.M. Kirov

Department of Therapy for the Postgraduate Education of Physicians № 2

Әдебиет тізімі

  1. Каратеев А.Е., Насонов Е.Л. НПВП-ассоциированная патология ЖКТ: реальное состояние дел в России. РМЖ. 2006;(15):1073- 78.
  2. Chan F., Lanas A., Scheiman J., Berger M.F., Nguyen H., Goldstein J.L. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;(376):173- 79.
  3. Cryer B. Gastrointestinal safety of low-dose aspirin. Am. J. Manag. Care. 2002; 8(Suppl 22):S701-708.
  4. Поражения органов пищеварения, индуцированные приемом нестероидных противовоспалительных препаратов/ Под общ. ред. А.В. Шаброва, Ю.П. Успенского. СПб., 2013. 283 с.
  5. Bigard M., Pelletier A. Esophageal complications of non steroidal antiinflammatory drugs. Gastroenterol. Clin. Biol. 2004;3:58-61.
  6. Avidan B., Sonnenberg A., Schnell T., Sontag S. Risk factors for erosive reflux esophagitis: a case-control study. Am. J. Gastroenterol. 2001;96:41-6.
  7. Semble E., Wu W., Castell D. Nonsteroidal antiinflammatory drug and esophageal injury. Semin. Arthritis Rheum. 1989;19:99-109.
  8. Sugawa C., Takekuma Y., Lucas C., Amamoto H. Bleeding esophageal ulcers caused by NSAIDs. Surg. Endosc. 1997;11:143-46.
  9. Bassotti G., Bucaneve G., Furno P. Double-blind, placebo-controlled study on effect of diclofenac sodium and indomethacin on postprandial gastric motility in men. Dig. Dis. Sci. 1998;43:1172-76.
  10. Kenneth D. Gastroesophageal reflux and asthma in the elderly patient. J. Allerg. Clin. Immunol. 1997;17(4):645-58.
  11. Каратеев А.Е., Успенский Ю.П., Пахомова И.Г., Насонов Е.Л. Прием НПВП и патология пищевода: связь с основными симптомами гастроэзофагеальной рефлюксной болезни (ГЭРБ), частота развития и факторы риска эрозивного эзофагита. Эксперим. и клин. гастроэнтерол. 2008;3:11-6.
  12. Hawkey C.J., Talley N.J., Scheiman J.M., et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Research & Therapy. 2007;9:R17.
  13. Ruszniewski P., Soufflet C., Barthelemy P., Colin R. NSAIDs intakes is a risk factor for gastroesophageal reflux. Gut. 2006;55(V):Ä267.
  14. Пахомова И.Г., Хорошинина Л.П. НПВП-индуцированная эзофагопатия: просто ГЭРБ или еще одна нозологическая единица? Фарматека. 2016;15:39-43.
  15. Taha A., Angerson W., Morran C. Correlation between erosive oesophageal and gastroduodenal diseases. The influence of aspirin, simple analgesics, and Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. 2002;14:1313-17.
  16. Kim S., Hunter J., Wo J. NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? J. Clin. Gastroenterol. 1999;29:32-4.
  17. Yeomans N., Lanas A., Labenz J., et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am. J. Gastroenterol. 2008, 103(10):2465-73.
  18. Пахомова И.Г., Успенский Ю.П., Едемская М.А., Егошина В.А., Каратеев А.Е. Поражения пищевода у больных остеоартрозом, принимающих нестероидные противовоспалительные препараты. Практическая медицина. 2012;3:86-90.
  19. Laine L., Curtis S., Cryer B., Kaur A., Cannon C. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and reumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: a randomized comparison. Lancet. 2007;369:465-73.
  20. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Рациональное применение нестероидных противовоспалительных препаратов. Клинические рекомендации / Под ред. А.Е. Каратеева. М.,2015. Интернет-ресурс-painrussia.ru
  21. Smale S., Tibbie J., Sigthorsson G., Bjarnason I. Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine. Best Pract. Res. Clin. Gastroenterol. 2001;15(5):732-38.
  22. Morris A.J., Madhok R., Sturrock R.D., Capell H.A., MacKenzie J.F. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroi-dal antiinflammatory drugs. Lancet. 1991;337(8740):520.
  23. Ширинская Н.В., Ахмедов В.А. НПВП-гастропатии: проблемы диагностики, лечения и контроля качества оказания медицинской помощи. М., 2011. 116 с.
  24. Каратеев А.Е., Насонова В.А. Энтеропатия, индуцированная нестероидными противовоспалительными препаратами. Тер. архив. 2004;2:79-82.
  25. Lim Y.J., Chun H.J. Recent Advances in NSAIDs-lnduced Enteropathy Therapeutics: New Options, New Challenges. Gastroenterol. Res. Pract. 2013;Article ID 761060.
  26. Вахрушев Я.М., Загребина Е.А. Энтеропатия, индуцированная нестероидными противовоспалительными препаратами (пато генез, диагностика, лечение). Тер. архив. 2012;(5):74-9.
  27. Smalley W.E., Griffin M.R., Fought R.L., Ray W.A. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J. Gen. Intern. Med. 1996;11:461-69.
  28. Schneider A.R., Benz C., Riemann J.F. Adverse effects of nonsteroidal anti-inflammatory drugs on the small and large bowel. Endoscopy. 1999;31:761-67.
  29. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Гастроэзофагеальная рефлюксная болезнь. Клинические рекомендации. Российская Гастроэнтерологическая Ассоциация. 2014. М., 23 с.
  30. Bliesath H., Huber R., Hartmann M., Luhmann R., Wurst W. Dose linearity of the pharmacokinetics of the new H+/K+-ATPase inhibitor pantoprazole after single intravenous administration. Int. J. Clin. Pharmacol. Ther 1994;32(1):44-50.
  31. Swidsinski A., Loaning-Baucke V., Bengmark S., Lochs H., Dörffel Y. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm. Bowel Dis. 2007;13(1):51-6.
  32. D'Incà R., Paccagnella M., Cardin R., et al. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis World J. Gastroenterol. 2013;19(34):5665-70.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2017